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S332 Poster Session IIcells in 15 assays. BM chimerism was at least 10% lower than PB,
M or T cell chimerism in 9/62 assays while PB chimerism was at
least 10% lower than BM chimerism twice. Engraftment (.90%
donor chimerism) occurred in at least one cell line in 124 of 140
pts. The vast majority of pts achieved this by day 60 post-SCT.
28 pts subsequently lost full chimerism; 25 in association with dis-
ease (dx) progression, 3 without progression. 33 pts had dx progres-
sion and/or died without losing full donor chimerism. 3 pts
achieved only myeloid donor chimerism; all are alive without dx
progression. 4 pts had testing but did not report results. With a me-
dian follow up of 12 mos, 85 pts are alive, 56 without dx progres-
sion and with full donor chimerism. Chimerism is commonly
performed following RIC regimens but practices vary widely even
within centers and individual pts. Although loss of donor chime-
rism is most commonly related to dx progression, maintenance of
chimerism does not exclude dx progression, bringing into question
the role of serial monitoring. Outside of a research protocol, for pts
receiving IV busulfan-based RIC, chimerism at a single time point
(d60) to confirm engraftment with no further routine testing
would be cost effective.Table 1. Patient Characteristics
Characteristics All FLT3/ITD 2 FLT3/ITD +
Patients: (n 5 ) 75 59 (78.7%) 16 (21.3%)
Age: (median in years) 49 47.9 50.6
Gender:
Female: 38 (50.7%) 30 8
Male: 37 (49.3%) 29 8
WBC at diagnosis: (median) 15 30.9 34.0
Karyotype:
Normal: 36 (48%) 24 12
Abnormal: 37 (49.3%) 33 4
Unknown: 2 (2.6%) 2 0
Conditioning Regimen:
Myeloablative: 42 (56%) 31 11
Reduced Intensity Conditioning: 33 (44%) 28 5
Donor Type:
Matched Related: 35 (46.7%) 29 6
Matched Unrelated: 29 (38.7%) 24 5
Umbilical Cord: 7 (9.3%) 4 3
Haploidentical: 4 (5.3%) 2 2
Stem Cell Source:
PBSCT: 55 (73.3%) 45 10
Bone Marrow: 13 (17.4%) 10 3
Umbilical Cord: 7 (9.3%) 4 3
GVHD prophylaxis:
CSA/MTX: 39 (52%) 31 8
CSA/MMF: 25 (33.3%) 22 3
FK/MMF: 8 (10.7%) 5 3
Other: 3 (4%) 1 2
Use of Thymoglobulin:
Yes: 18 (24%) 13 5
No: 57 (76%) 46 11
Graft Failure:
Yes: 2 (2.5%) 1 1
No: 73 (97.5%) 58 15
Relapsed:
Yes: 21 (28%) 13 (22%) 8 (50%)
No: 54 (72%) 46 (78%) 8 (50%)
Alive:
Yes: 45 (60%) 35 (59.3%) 10 (63%)
No: 30 (40%) 24 (40.7%) 6 (37%)
Abbreviations: CSA indicates cyclosporine; MTX, methotrexate; MMF,
Mycofenolate Mofetil; FK, FK 507; PBSCT, peripheral blood stem cell
transplant.345
USE OF CYCLOSPORINE IS ASSOCIATEDWITH THE INCREASE IN PRE-EN-
GRAFTMENT SYNDROME AFTER MYELOABLATIVE DUAL CORD BLOOD
TRANSPLANTATION
Kanda, J.1, Kaynar, L.1, Kanda, Y.2, Prasad, V.K.3, Parikh, S.H.3,
Rizzieri, D.A.1, Long, G.D.1, Sullivan, K.M.1, Gasparetto, C.1,
Chute, J.P.1, Morris, A.1, Winkel, S.1, McPherson, J.1, Kurtzberg, J.3,
Chao, N.J.1, Horwitz, M.E.1 1Duke University Medical Center,
Durham, NC; 2Saitama Medical Center, Jichi Medical University,
Saitama, Japan; 3Duke University Medical Center, Durham, NC
Background: High fever and/or rash prior to neutrophil engraft-
ment is frequently observed after umbilical cord blood transplanta-
tion (UCBT) and is called pre-engraftment syndrome (PES). Few
studies have evaluated risk factors and treatment response for PES.
Therefore, we retrospectively characterized PES in 57 consecutive
engrafted patients (. 5 12 years old) who received myeloablative
dual UCBT.
Methods: Patients received 2 UCB grafts that were at least 4 of 6
HLA-matched with the recipient. All patients received TBI (. 5
13.2Gy)-based myeloablative conditioning. Tacrolimus (Tac)
(n 5 35) or cyclosporine (CyA) (n 5 22) combined with mycophe-
nolate mofetil was used as a GVHD prophylaxis. CyA was more
commonly used in patients receiving a more intensive conditioning
regimen containing cyclophosphamide. PES was defined as the
presence of either non-infectious fever (. 5 38.5C) and/or rash
prior to or on the day of neutrophil engraftment. The incidence
of PES and overall survival (OS) rate was estimated using the Ka-
plan-Meier method. Incidence of acute GVHD (aGVHD) was es-
timated using the cumulative incidence method. Factors with
p \0.20 in the univariate analysis were used in the multivariate
model.
Results: Median age of patients was 28 (range 12-58) years. The
median combined total nucleated cell dose was 4.8 (range, 2.8-
10.1) x 107/kg. The incidence (95% CI) of PES, grades II-IV
and III-IV aGVHD were 0.77 (0.63-0.86), 0.60 (0.46-0.71), and
0.32 (0.20-0.44), respectively. Multivariate analysis showed that
the use of CyA was the only significant variable associated with
PES (CyA vs. Tac; HR 3.25, p 5 0.003). The use of CyA was
also a significant variable for grade III-IV aGVHD (HR 3.02,
p 5 0.020). Twenty-four of 44 patients with PES were treated
with . 5 1 mg/kg of methylprednisolone or prednisone, which re-
sulted in complete and partial response at day 7 in 10 and 14 pa-
tients, respectively. Acute GVHD developed in 7 of 20 patients
who did not receive systemic treatment for PES (grades II in 3
and grades III-IV aGVHD in 4). Although OS in the Tac group
tended to be higher than in the CyA group, there was no statistical
difference between the two group (p 5 0.102).
Conclusion:GVHD prophylaxis with CyA vs. Tac was a risk factor
for both PES and grades III-IV aGVHD after myeloablative dual
UCBT in our cohort. The impact of GVHD prophylaxis (CyA vs.
Tac) in UCBT will need to be confirmed in a prospective trial
with a uniform conditioning regimen.346
ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3/ITD POSITIVE
ACUTE MYELOID LEUKEMIA IN CR1: IMPLICATION FOR PERSONALIZED
THERAPY TO PREVENT EARLY RELAPSES
Sengsayadeth, S.M.1, Jagasia, M.1, Engelhardt, B.G.1, Kassim, A.1,
Strickland, S.A.1, Goodman, S.1, Lucid, C.1, Vnencek-Jones, C.L.2,
Greer, J.P.1, Savani, B.N.1 1Vanderbilt University Medical Center,
Nashville, TN; 2Vanderbilt University Medical Center, Nashville, TN
Objective: Fms-Like Tyrosine kinase 3/Internal Tandem Duplica-
tion (FLT3/ITD) mutation in patients with acute myeloid leukemia
(AML) is associated with shorter disease free survival (DFS) and
overall survival (OS). Although evidence from prospective trials is
lacking, allogeneic stem cell transplantation (allo-SCT) is often con-
sidered in patients with FLT3/ITD+ AML in first complete remis-
sion (CR1). Prognostic significance of FLT3/ITD mutation
compared to other conventional prognostic markers in patients re-
ceiving allo-SCT in AML-CR1 is unknown.
Methods: 79 consecutive patients with AML in CR1 received allo-
SCT between June 2005 and May 2011 at Vanderbilt University
Medical Center. 4 patients with unknown FLT3/ITD status were
excluded. The prognostic impact of FLT3/ITD mutation was eval-
uated in the context of other clinical prognostic and genetic risk fac-
tors.
Results: FLT3/ITDmutation was present in 16 (21%) of the 75 pa-
tients who underwent allo-SCT in CR1. There were no significant
differences in age, WBC at diagnosis, or transplant characteristics
Poster Session II S333between the groups except a higher percentage of normal cytogenet-
ics in patients with FLT3/ITD+ (p 5 0.025).Two year OS, DFS,
non-relapse mortality (NRM), and relapse of cohort were 60.8%,
55.8%, 18.0% and 31.3%, respectively. Univariate analysis showed
FLT3/ITD+ compared to FLT3/ITD- patients was significantly as-
sociated with inferior DFS (2 year DFS: 19% vs. 64%, p\0.0027),
increased risk of relapse (1 year: 59%vs. 19%, p\0.0009), and a trend
towards decreased OS (p 5 0.08). 5 of the 16 FLT3/ITD+ patients
were also positive for NPM1, which did not impact outcome. Mul-
tivariate analysis using the Cox proportion hazard regression model
confirmed that FLT3/ITD+ mutations independently predicted
a shorter DFS (hazard ratio [HR], 3.0; 95% CI, 1.4-6.5; p 5
0.004) and increased risk of relapse (HR, 4.9; 95% CI, 2.0-12.3,
p 5 0.001). Time to relapse in patients with FLT3/ITD+ was very
short with 100 days cumulative risk of 45%.
Conclusion:Our data suggests that allo-SCT in FLT3/ITD+ AML
CR1 does not appear to overcome the poor prognostic value, and
these patients remain at high risk of early relapse even after allo-
SCT.While our study is limited by small size, this further illustrates
the urgent need for larger prospective studies to validate the efficacy
of allo-SCT in CR1 and the need to design therapy targeting FLT3/
ITD either prior to or early-post transplant to decrease relapse for
this specific subgroup.347
THIOTEPA (Tt), BUSULFAN (Bu), AND CLOFARABINE (Clo) AS A CONDI-
TIONING THERAPY FOR ALLOGENEIC HEMATOPOETIC STEM CELL
TRANSPLANT FOR PATIENTS WITH HIGH RISK MALIGNANCIES: UP-
DATED RESPONSE AND ENGRAFTMENT DATA
Worth, L.L.1, Andersson, B.S.2, Kelly, S.S.1, Petropoulos, D.1, Lee, D.A.1,
Kebriaei, P.2, Cooper, L.J.N.1, Champlin, R.E.2 1M D Anderson Cancer
Center, Houston, TX; 2M D Anderson Cancer Center, Houston, TX
Introduction: Fludarabine (F) and Busulfan (Bu) is a well-tolerated
conditioning regimen for allo HSCT. New nucleoside antimetabo-
lites are available with the potential for improved anti-tumor effect.
We substituted Clofarabine (Clo) for F for its better antileukemic ac-
tivity. To address the blood-brain barrier we added Thiotepa (Th),
a polyfunctional alkylating agent. These data report on combining
the Th + (IV)Bu + Clo in a conditioning regimen for high risk pa-
tients.
Patients and Methods: 31 patients received Th 5 mg/kg over 1 hr.
Bu was administered x 3 days over 3 hr to a daily AUC of 5,000
mcMol-min +/-10%. Clo 40mg/m2 was infused over 1 hr daily x 4
days. 29 patients are evaluable for engraftment and survival beyond
day + 30. M/F: 18/13. Median age 18 y (range 2-60). 16 patients
had AML [IF (2), relapse refractory (4), relapse untx(3), CR2 (6),
. CR2 (1)]. 14 patients had ALL [CR1 (1), CR2 (4), CR3 (5), Re-
lapse sensitive (2), relapse resistant (1) relapse untx(1)]. One patient
had CML ($ 3 CP). 7 had received prior transplants this being their
2nd (4), 3rd (2), 4th (1)]. GVHDprophylaxis was tacrolimus andmini-
MTX or tacrolimus and MMF (CB recipients). Those with one
Ag-mism or unrelated grafts received rabbit-ATG. Stem cell sources
included cord (17); MUD-apheresis (4), MUD-BM (5), MSD–
apheresis (4) MSD-BM (1).
Results: 15 patients are alive although 3 have relapsed (d132, d139,
d231) for a median OS 320 d (120-833). Common regimen-related
toxicities were GI and esophagitis. Self-limited hemorrhagic cystitis
due to BK virus occurred in 7 patients. Deaths from VOD/Pulmo-
nary hemorrhage (4) occurred in patients receiving Gemtuzumab
Ozogamicin or Inotuzumab ozogamicin therapy. Acute GVHD oc-
curred in  50% of all patients Grade II-IV (7). None (12) NE (4).
Chronic GVHD occurred in 5 patients, none (19), NE (7). Deaths
(16) were due to relapse (9) PFS 90 d (30-279), late infection (1)
d 259. The other 6 patients who died all received ozogamicin ther-
apy. PB microsatellite chimerism at day +30 showed 100% donor
T cell and myeloid cells in all but 4 patients who went on to relapse.
Conclusion: This regimen is overall safe unless administered after
recent ozogamicin therapy. Significantly, patients with refractory
disease at the time of HSCT achieved a CR. Engraftment in recipi-
ents of UCB transplants was robust (medium 18 days). In aggregate,
this chemotherapy regimen provided an anti-leukemia effect and
warrants further investigation.348
ADOPTIVE IMMUNOTHERAPY USING ANTI-THYMOCYTE GLOBULIN AND
REDUCED INTENSITY TOTAL BODY IRRADIATION; A COST-EFFECTIVE
STRATEGY FOR ALLOGENEIC STEM CELL TRANSPLANTATION
Shickle, L.M.2, Hazlett, A.F.1, Jin, Y.2, Sabo, R.T.1, Korshin, T.2,
Chung, H.M.1, McCarty, J.M.1, Clark, W.B.1, Toor, A.A.1,
Roberts, C.H.1 1VCU Massey Cancer Center, Richmond, VA; 2VCU
Massey Cancer Center, Richmond, VA
Allogeneic stem cell transplants (SCT) conditioned with conven-
tional regimens continue to be fraughtwith complications, increasing
resource utilization and downstream costs associated with these
procedures. We have developed an investigational conditioning reg-
imen, incorporating anti-thymocyte globulin (ATG; Thymoglobu-
lin, Sanofi-Aventis) and reduced-intensity total body irradiation,
with the goal of reducing complications following SCT
(NCT00709592). To determine the cost savings associated with
the use of this regimen, we performed a retrospective analysis of di-
rect costs incurred during the first 100 days following SCT.We com-
pared the investigational group of patients (IG; n5 25) with a control
group transplantedduring the same timeperiodand conditionedwith
either reduced intensity busulfan ormelphalan + fludarabine contain-
ing regimens (CG; n5 32). The IG and CG differed in age (57 vs. 53
years; F-Test, p5 0.04), number of prior regimens (4 vs. 2; p\0.01),
and disease distribution (p\0.001), but had a similar proportion of
matched related and unrelated donors (p 5 0.12). At a median fol-
low-up of 20months in the IG and 12months in the CG, the survival
in the two groups is similar (one-year K-M survival estimate 73% vs.
53%, Log Rank p 5 0.16). Inpatient hospitalization following SCT
was shorter for IG, 17 (67) days, compared to the CG, 24 (616)
days (p 5 0.02). Direct cost incurred during the study period was
lower for the IG ($121,103 6 47,292) compared to the CG
($194,392 6 93,760) (p\0.01), this despite the entire IG surviving
to day 100 (4 deaths in the CG). When patients who relapsed or
died during this period were excluded from analysis the cost differ-
ence remained in favor of the IG, $118,546 6 48,567 vs. $188,239
6 92,484 for the CG (p\0.01). Table 1 displays the trends in the
cost incurred over time for the investigational and control groups.
The cost savings spanned a variety of categories, including pharma-
ceutical, blood bank, laboratory and inpatient charges. We conclude
that despite being heavily pretreated, patients conditioned with the
investigational ATG + TBI regimen spent fewer days in the hospital
and had a lower cost associated with transplantation. Given the cur-
rent economic climate, our findings suggest that rethinking conven-
tional methods of reduced-intensity conditioning, with emphasis on
adoptive immunotherapy rather than dose intensity,may improve the
cost-effectiveness of allogeneic SCT.
Table 1. Total and InpatientCostsUpToDay100FollowingSCT
Time Period Control Group Investigational Group p ValueTotal Costs
1-100 Days $194,392 $121,103 <0.01
1-30 Days $70,750 $49,306 <0.01
31-60 Days $30,216 $16,028 <0.01
61-100 Days $37,841 $16,709 0.05
Inpatient Costs
1-100 Days $51,442 $36,084 0.04
1-30 Days $26,266 $21,411 0.06
31-60 Days $7,732 $1,706 0.02
61-100 Days $11,972 $2,008 0.04The costs are mean values and standardized to FY 2012 $. The p-value
was calculated using analysis of variance (F test).
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ENCOURAGING SURVIVAL FOR PATIENTS WHO HAD A SECOND UMBILI-
CAL CORD BLOOD TRANSPLANT FOR GRAFT FAILURE
Lund, T.C.1, Verneris, M.R.1, Tolar, J.1, Cao, Q.2, Weisdorf, D.J.2,
Wagner, J.E.2, Brunstein, C.G.2 1University of Minnesota, Minneapolis,
MN; 2University of Minnesota, Minneapolis, MN
After umbilical cord blood transplantation (UCBT), the 10-15%
risk of graft failure (GF) remains a significant source or morbidity
